RESUMEN
153 SmEDTMP was obtained from enriched 153Sm irradiated at the 5 MW Chilean Research reactor and labelled at a molar ratio of 15:1 pH 7.5. Biodistribution, autoradiography, radiochemical purity tests were done for evaluation. 40 patients were treated with 37-55 MBq/kg weight. Bone scans using 99mTcHMDP were obtained prior and after treatment. Bone marrow depression was observed in 37 percent of them and normal liver function in all of them. In 45 percent the pain dissapear completely, in 22,5 percent significantly decreased and partially in 30 percent. In 17 patients more than one dosis was injected. Our preliminary results indicate that 153 SmEDTMP is a promising radiotherapeutic agent for palliative treatment of metastasic bone cancer pain and encourage its use specially because it can be produced in countries with low economic resources, thus a large number of patients can get the benefits of this new procedure
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Dolor Intratable/radioterapia , Samario/uso terapéutico , Neoplasias Óseas/complicaciones , Radioisótopos/uso terapéutico , Cuidados Paliativos , Metástasis de la NeoplasiaRESUMEN
El uso de anticuerpos monoclonales en medicina nuclear ha constituído una de las materias del mas alto interés en la investigación biomédica de la última década, por el impacto que ellos podrán tener en un futuro no muy lejano en el diagnóstico y terapia de enfermedades cancerosas. Los autores explican en el presente trabajo, qué son los anticuerpos monoclonales y como se producen, presentando las aplicaciones y problemas actuales inherentes a su uso, para esbozar sus perspectivas futuras